Is DBVT or PGEN more profitable?

Precigen has a net margin of -183.98% compared to DBV Technologies' net margin of -3,506.53%. Precigen's return on equity of 423.75% beat DBV Technologies' return on equity. Company Net Margins Return on Equity Return on Assets DBV Technologies -3,506.53% -119.33% -84.43% Precigen -183.98% 423.75% 84.39%

Does the media prefer DBVT or PGEN?

In the previous week, Precigen had 2 more articles in the media than DBV Technologies. MarketBeat recorded 14 mentions for Precigen and 12 mentions for DBV Technologies. Precigen's average media sentiment score of 0.69 beat DBV Technologies' score of 0.24 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Precigen 3 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DBVT or NAMS?

In the previous week, DBV Technologies had 6 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 12 mentions for DBV Technologies and 6 mentions for NewAmsterdam Pharma. DBV Technologies' average media sentiment score of 0.24 beat NewAmsterdam Pharma's score of 0.14 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral NewAmsterdam Pharma 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate DBVT or GMTX?

DBV Technologies currently has a consensus target price of $48.50, suggesting a potential upside of 348.87%. Given DBV Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe DBV Technologies is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor BEAM or DBVT?

In the previous week, DBV Technologies had 5 more articles in the media than Beam Therapeutics. MarketBeat recorded 12 mentions for DBV Technologies and 7 mentions for Beam Therapeutics. DBV Technologies' average media sentiment score of 0.24 beat Beam Therapeutics' score of 0.23 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DBV Technologies 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to DBVT or IRON?

In the previous week, DBV Technologies had 7 more articles in the media than Disc Medicine. MarketBeat recorded 12 mentions for DBV Technologies and 5 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.41 beat DBV Technologies' score of 0.24 indicating that Disc Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Disc Medicine 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

DBV Technologies (DBVT) Competitors

$10.55 -0.66 (-5.89%)

Closing price 04:00 PM Eastern

Extended Trading

$10.54 -0.01 (-0.05%)

As of 04:43 PM Eastern

Compare

DBVT vs. PGEN, NAMS, GMTX, BEAM, and IRON

Should you buy DBV Technologies stock or one of its competitors? DBV Technologies's main competitors and comparable companies include Precigen (PGEN), NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), Beam Therapeutics (BEAM), and Disc Medicine (IRON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does DBV Technologies compare to Precigen?

DBV Technologies (NASDAQ:DBVT) and Precigen (NASDAQ:PGEN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

DBV Technologies has higher earnings, but lower revenue than Precigen. Precigen is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	120.46	-$146.95M	-$3.51	N/A
Precigen	$9.68M	305.28	-$250.64M	-$1.04	N/A

DBV Technologies has a beta of -1.04, indicating that its stock price is 204% less volatile than the broader market. Comparatively, Precigen has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

In the previous week, Precigen had 2 more articles in the media than DBV Technologies. MarketBeat recorded 14 mentions for Precigen and 12 mentions for DBV Technologies. Precigen's average media sentiment score of 0.69 beat DBV Technologies' score of 0.24 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Precigen	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

DBV Technologies currently has a consensus price target of $48.50, suggesting a potential upside of 348.87%. Precigen has a consensus price target of $13.67, suggesting a potential upside of 64.88%. Given DBV Technologies' higher probable upside, equities research analysts clearly believe DBV Technologies is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Precigen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Precigen has a net margin of -183.98% compared to DBV Technologies' net margin of -3,506.53%. Precigen's return on equity of 423.75% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Precigen	-183.98%	423.75%	84.39%

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by company insiders. Comparatively, 41.4% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Precigen beats DBV Technologies on 12 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to NewAmsterdam Pharma?

DBV Technologies (NASDAQ:DBVT) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

DBV Technologies presently has a consensus price target of $48.50, suggesting a potential upside of 348.87%. NewAmsterdam Pharma has a consensus price target of $49.73, suggesting a potential upside of 115.83%. Given DBV Technologies' higher probable upside, research analysts clearly believe DBV Technologies is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

DBV Technologies has a net margin of -3,506.53% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

DBV Technologies has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	120.46	-$146.95M	-$3.51	N/A
NewAmsterdam Pharma	$22.50M	122.41	-$203.82M	-$2.16	N/A

DBV Technologies has a beta of -1.04, meaning that its share price is 204% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

In the previous week, DBV Technologies had 6 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 12 mentions for DBV Technologies and 6 mentions for NewAmsterdam Pharma. DBV Technologies' average media sentiment score of 0.24 beat NewAmsterdam Pharma's score of 0.14 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NewAmsterdam Pharma beats DBV Technologies on 11 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to Gemini Therapeutics?

DBV Technologies (NASDAQ:DBVT) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

In the previous week, DBV Technologies had 12 more articles in the media than Gemini Therapeutics. MarketBeat recorded 12 mentions for DBV Technologies and 0 mentions for Gemini Therapeutics. DBV Technologies' average media sentiment score of 0.24 beat Gemini Therapeutics' score of 0.00 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
DBV Technologies	Neutral
Gemini Therapeutics	Neutral

Gemini Therapeutics has lower revenue, but higher earnings than DBV Technologies. Gemini Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	120.46	-$146.95M	-$3.51	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

DBV Technologies currently has a consensus target price of $48.50, suggesting a potential upside of 348.87%. Given DBV Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe DBV Technologies is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

DBV Technologies has a beta of -1.04, meaning that its stock price is 204% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

Gemini Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Gemini Therapeutics' return on equity of -38.78% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Summary

Gemini Therapeutics beats DBV Technologies on 8 of the 15 factors compared between the two stocks.

How does DBV Technologies compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and DBV Technologies (NASDAQ:DBVT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 1.1% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, DBV Technologies had 5 more articles in the media than Beam Therapeutics. MarketBeat recorded 12 mentions for DBV Technologies and 7 mentions for Beam Therapeutics. DBV Technologies' average media sentiment score of 0.24 beat Beam Therapeutics' score of 0.23 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DBV Technologies	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Beam Therapeutics has a net margin of -54.75% compared to DBV Technologies' net margin of -3,506.53%. Beam Therapeutics' return on equity of -30.71% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

Beam Therapeutics has higher revenue and earnings than DBV Technologies. Beam Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	17.98	-$79.99M	-$0.86	N/A
DBV Technologies	$5.64M	120.46	-$146.95M	-$3.51	N/A

Beam Therapeutics has a beta of 2.2, indicating that its stock price is 120% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -1.04, indicating that its stock price is 204% less volatile than the broader market.

Beam Therapeutics presently has a consensus target price of $49.00, suggesting a potential upside of 101.44%. DBV Technologies has a consensus target price of $48.50, suggesting a potential upside of 348.87%. Given DBV Technologies' higher possible upside, analysts clearly believe DBV Technologies is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Beam Therapeutics beats DBV Technologies on 12 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to Disc Medicine?

DBV Technologies (NASDAQ:DBVT) and Disc Medicine (NASDAQ:IRON) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, DBV Technologies had 7 more articles in the media than Disc Medicine. MarketBeat recorded 12 mentions for DBV Technologies and 5 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.41 beat DBV Technologies' score of 0.24 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by company insiders. Comparatively, 3.8% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

DBV Technologies currently has a consensus target price of $48.50, indicating a potential upside of 348.87%. Disc Medicine has a consensus target price of $110.18, indicating a potential upside of 71.76%. Given DBV Technologies' higher probable upside, research analysts clearly believe DBV Technologies is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Disc Medicine has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Disc Medicine's return on equity of -37.17% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Disc Medicine	N/A	-37.17%	-33.65%

DBV Technologies has a beta of -1.04, indicating that its share price is 204% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

DBV Technologies has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	120.46	-$146.95M	-$3.51	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

Summary

Disc Medicine beats DBV Technologies on 9 of the 15 factors compared between the two stocks.

Get DBV Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DBVT vs. The Competition

Export

Metric	DBV Technologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$663.38M	$3.84B	$7.10B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-3.01	12.99	274.33	26.05
Price / Sales	117.62	1,288.68	601.06	89.40
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	2.51	16.63	10.92	6.31
Net Income	-$146.95M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-8.74%	-3.05%	-2.11%	-1.67%
1 Month Performance	-22.48%	-10.75%	-6.34%	-3.94%
1 Year Performance	-13.88%	21.11%	8.81%	2.77%

DBV Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DBVT DBV Technologies	3.8112 of 5 stars	$10.55 -5.9%	$48.50 +359.7%	+11.3%	$663.38M	$5.64M	N/A	161	Analyst Forecast Gap Down High Trading Volume
PGEN Precigen	3.894 of 5 stars	$8.05 +3.0%	$13.67 +69.9%	+145.8%	$2.87B	$9.68M	N/A	47	Gap Up
NAMS NewAmsterdam Pharma	3.5986 of 5 stars	$23.90 +1.3%	$49.73 +108.1%	-17.7%	$2.86B	$22.50M	N/A	100	Insider Trade
GMTX Gemini Therapeutics	N/A	$64.92 -0.5%	N/A	-0.9%	$2.81B	N/A	N/A	30	High Trading Volume
BEAM Beam Therapeutics	2.3869 of 5 stars	$24.57 +1.4%	$49.00 +99.5%	+1.1%	$2.54B	$139.74M	N/A	540	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DBVT) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DBV Technologies (DBVT) Competitors

DBVT vs. PGEN, NAMS, GMTX, BEAM, and IRON

How does DBV Technologies compare to Precigen?

Summary

How does DBV Technologies compare to NewAmsterdam Pharma?

Summary

How does DBV Technologies compare to Gemini Therapeutics?

Summary

How does DBV Technologies compare to Beam Therapeutics?

Summary

How does DBV Technologies compare to Disc Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DBV Technologies (DBVT) Competitors

DBVT vs. PGEN, NAMS, GMTX, BEAM, and IRON

How does DBV Technologies compare to Precigen?

Which has preferable earnings & valuation, DBVT or PGEN?

Which has more volatility & risk, DBVT or PGEN?

Does the media prefer DBVT or PGEN?

Do analysts recommend DBVT or PGEN?

Is DBVT or PGEN more profitable?

Do insiders and institutionals hold more shares of DBVT or PGEN?

Summary

How does DBV Technologies compare to NewAmsterdam Pharma?

Do analysts prefer DBVT or NAMS?

Is DBVT or NAMS more profitable?

Do institutionals and insiders have more ownership in DBVT or NAMS?

Which has higher earnings & valuation, DBVT or NAMS?

Which has more volatility and risk, DBVT or NAMS?

Does the media refer more to DBVT or NAMS?

Summary

How does DBV Technologies compare to Gemini Therapeutics?

Does the media refer more to DBVT or GMTX?

Which has preferable earnings and valuation, DBVT or GMTX?

Do analysts rate DBVT or GMTX?

Do insiders and institutionals have more ownership in DBVT or GMTX?

Which has more volatility and risk, DBVT or GMTX?

Is DBVT or GMTX more profitable?

Summary

How does DBV Technologies compare to Beam Therapeutics?

Do institutionals & insiders have more ownership in BEAM or DBVT?

Does the media favor BEAM or DBVT?

Is BEAM or DBVT more profitable?

Which has stronger valuation and earnings, BEAM or DBVT?

Which has more risk and volatility, BEAM or DBVT?

Do analysts recommend BEAM or DBVT?

Summary

How does DBV Technologies compare to Disc Medicine?

Does the media refer more to DBVT or IRON?

Do insiders & institutionals hold more shares of DBVT or IRON?

Do analysts rate DBVT or IRON?

Is DBVT or IRON more profitable?

Which has more volatility & risk, DBVT or IRON?

Which has higher earnings & valuation, DBVT or IRON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools